Kura Oncology (KURA) Receivables - Accured (2020 - 2026)

Kura Oncology (KURA) has 7 years of Receivables - Accured data on file, last reported at $4.3 million in Q1 2026.

• Receivables - Accured for Q1 2026 came in at $4.3 million, up 10.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.3 million (up 10.26% YoY), and the FY2025 annual result was $3.8 million, up 15.15% from the prior year.
• Receivables - Accured climbed to $4.3 million in Q1 2026 per KURA's latest filing, from $3.8 million in the prior quarter.
• Over five years, Receivables - Accured peaked at $4.3 million in Q1 2026 and troughed at $900000.0 in Q4 2022.
• A 5-year average of $2.1 million and a median of $1.6 million in 2022 frame the typical range for Receivables - Accured.
• The sharpest annual moves came in 2023 and 2024: Receivables - Accured tumbled 43.75% in 2023, then jumped 200.0% in 2024.
• A 5-year view of Receivables - Accured shows it stood at $900000.0 in 2022, then advanced by 22.22% to $1.1 million in 2023, then jumped by 200.0% to $3.3 million in 2024, then rose by 15.15% to $3.8 million in 2025, then gained by 13.16% to $4.3 million in 2026.
• Business Quant data shows KURA's Receivables - Accured at $4.3 million in Q1 2026, $3.8 million in Q4 2025, and $3.3 million in Q3 2025.